-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose ...
Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high t...
Sterile fill/finish capacity added in Lee, MA, and injectable assembly and packaging capacity added in the Netherlands, Belgium, Allent...
SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation Th...
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ pl...
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have ...
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rar...
Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...
-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s p...
NMPA’s response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 Belite Bio, Inc. (NASDAQ...
SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis...
© 2025 Biopharma Boardroom. All Rights Reserved.
